NCT02489903 2025-03-17
RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
EpicentRx, Inc.
Phase 2 Completed
Clinical Trials
13 trialsNCT05966194 2024-11-15
KEVLARx
EpicentRx, Inc.
Phase 2 Recruiting
NCT03515538 2024-11-04
PREVLAR
EpicentRx, Inc.
Phase 2 Completed
NCT01359982 2024-11-01
DINAMIC
EpicentRx, Inc.
Phase 1 Completed
NCT04525014 2024-10-31
PIRATE
EpicentRx, Inc.
Phase 1 Terminated
NCT05566041 2024-10-31
REPLATINUM
EpicentRx, Inc.
Phase 3 Active not recruiting
NCT02096354 2024-10-15
ROCKET
EpicentRx, Inc.
Phase 2 Completed
NCT02452970 2024-04-24
EPIC
EpicentRx, Inc.
Phase 2 Terminated
NCT03699956 2024-03-26
REPLATINUM
EpicentRx, Inc.
Phase 3 Terminated
NCT02801097 2022-05-17
PAYLOAD
EpicentRx, Inc.
Phase 1 Terminated
NCT02215512 2021-11-03
BRAINSTORM
EpicentRx, Inc.
Phase 1 Completed
NCT02518958 2019-11-18
PRIMETIME
EpicentRx, Inc.
Phase 1 Completed
NCT02096341 2016-01-21
A Phase 1 Pilot Study of the Subcutaneous (s.c.) Route to Facilitate the Administration of RRx-001
EpicentRx, Inc.
Phase 1 Terminated